Cancer Clinical Trial - Toray 950P1V02

CONDITION(S): Melanoma, Advanced Solid Tumors, Ovarian, Gastric, Bladder, Colorectal - TRIAL: A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Drug

TRK-950 + nivolumab or pembrolizumab

Trial Type

Interventional

Phase

Phase 1B

Condition

Melanoma Advanced solid tumors Ovarian cancer Gastric cancer Bladder cancer Colorectal cancer

Keywords

Melanoma | Advanced solid tumors | Ovarian cancer | Gastric cancer | Bladder cancer | Colorectal cancer